home · filing · 0001477932-23-007445
8-K filed October 6, 2023, 7:59 PM ET
CIK 0001404935
leadership
confidence high
sentiment neutral
materiality 0.70
THC Therapeutics CEO resigns; Scott Cox appointed interim CEO; change of control via preferred stock
THC Therapeutics, Inc.
Brandon Romanek resigned as CEO on Sept 29, 2023; Scott Cox appointed Interim CEO and board member.
Cox received 600,000 Series A Preferred shares at $0.30 each, each with 100 votes and convertible to 100 common shares.
Preferred stock issuance constitutes a change of control of THC Therapeutics.
Cox has over 20 years experience; currently CEO of Verde Bio Holdings (OTC: VBHI).
Shares were issued under Section 4(a)(2) and Rule 506(b) exemption.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2023-09-29
Filed October 6, 2023, 7:59 PM ET
Scott Cox was appointed as Interim CEO of the Company
Effective 2023-09-29
Filed October 6, 2023, 7:59 PM ET
as a member of its Board of Directors
Departed
Brandon Romanek
Chief Executive Officer
THC Therapeutics, Inc.
Effective 2023-09-29
Successor Scott Cox
Filed October 6, 2023, 7:59 PM ET
On September 29, 2023, Brandon Romanek resigned as CEO of THC Therapeutics, Inc.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Cox was appointed as Interim Chief Executive Officer at THC Therapeutics, Inc..
Action appointed
Role Interim Chief Executive Officer
Exact text from the filing
Scott Cox was appointed as Interim CEO of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Cox was appointed as Member of the Board of Directors at THC Therapeutics, Inc..
Action appointed
Role Member of the Board of Directors
Exact text from the filing
as a member of its Board of Directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brandon Romanek resigned as Chief Executive Officer at THC Therapeutics, Inc..
Action resigned
Role Chief Executive Officer
Exact text from the filing
On September 29, 2023, Brandon Romanek resigned as CEO of THC Therapeutics, Inc.
View on SEC.gov
Source: SEC EDGAR
accession 0001477932-23-007445
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.